Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...4950515253545556575859...266267»
  • ||||||||||  Cabometyx (cabozantinib tablet) / Exelixis
    Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker:  Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) -  Feb 24, 2023   
    P2,  N=105, Active, not recruiting, 
    N=514 --> 278 Recruiting --> Active, not recruiting | Trial completion date: Jan 2028 --> Aug 2027 | Trial primary completion date: Jul 2024 --> Feb 2024
  • ||||||||||  Retrospective data, Journal:  Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. (Pubmed Central) -  Feb 23, 2023   
    For newly diagnosed BMs, adding chemotherapy, EGFR-TKIs, and other innovative systemic agents (temozolomide, nitroglycerin, endostar, enzastaurin, and veliparib) to radiotherapy did not significantly prolong OS than radiotherapy alone; whereas radiotherapy + nitroglycerin showed significantly better CNS-PFS and ORR...For previously treated BMs, pembrolizumab + chemotherapy, nivolumab + ipilimumab, and cemiplimab significantly prolonged OS than chemotherapy alone...The value of surgery should also be emphasized. The result should be further confirmed by RCTs.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Review, Journal, Adverse events, Checkpoint inhibition:  Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. (Pubmed Central) -  Feb 22, 2023   
    Particularly, the difference between actual immune-related adverse events and paraneoplastic syndromes might be relevant. These findings might be of great value in establishing guidelines on how to manage ocular adverse events related to ICIs.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Dual Immunotherapy in the first-line advanced RCC: Why , who, when and how () -  Feb 21, 2023 - Abstract #HKSUO2023HKSUO_9;    
    Among the various immunotherapy combinations approved for first-line aRCC, nivolumab plus ipilimumab is the only combination that does not involve a VEGF-TKI and offers remarkably long and durable responses even at 5-year follow-up from CheckMate 214 trial. With that, we will take a closer look at the "Why, Who, When and How" about choosing dual immunotheraopy as the first-line treatment for aRCC.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Checkpoint inhibition:  CRUCIAL: Combination of Chemoradiation With Immunotherapy in Inoperable  (clinicaltrials.gov) -  Feb 21, 2023   
    P2,  N=8, Terminated, 
    Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024 N=130 --> 8 | Trial completion date: May 2022 --> Oct 2022 | Unknown status --> Terminated | Trial primary completion date: May 2022 --> Oct 2022; Poor accrual
  • ||||||||||  pepinemab (VX15) / Vaccinex, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Biomarker, Enrollment closed, Trial primary completion date:  VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma (clinicaltrials.gov) -  Feb 21, 2023   
    P1,  N=41, Active, not recruiting, 
    N=130 --> 8 | Trial completion date: May 2022 --> Oct 2022 | Unknown status --> Terminated | Trial primary completion date: May 2022 --> Oct 2022; Poor accrual Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed, Trial completion date, Trial primary completion date:  A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (clinicaltrials.gov) -  Feb 21, 2023   
    P1,  N=90, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Sep 2022
  • ||||||||||  GRANITE / Gritstone bio
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Checkpoint inhibition:  GO-004: A Study of a Personalized Neoantigen Cancer Vaccine (clinicaltrials.gov) -  Feb 17, 2023   
    P1/2,  N=29, Completed, 
    N=65 --> 120 Active, not recruiting --> Completed | N=214 --> 29 | Trial completion date: Mar 2023 --> Nov 2022 | Trial primary completion date: Jul 2022 --> Nov 2022